美金刚用于治疗痴呆症？

Memantine for dementia?

出版信息

Drug Ther Bull. 2003 Oct;41(10):73-6.

Abstract

Memantine (Ebixa--Lundbeck Ltd), an oral medicine, is available in the UK for treating "patients with moderately severe to severe Alzheimer's disease". It differs from other licensed dementia medicines in that it is an N-methyl-D-aspartate (NMDA) receptor antagonist. The company has claimed that, with memantine therapy, "improvements in activities of daily living help patients to maintain a degree of independence and be easier to care for, potentially avoiding the need for nursing home care". We assess the efficacy of memantine for dementia and discuss its place in the management of patients with Alzheimer's disease.

摘要

美金刚（易倍申——灵北公司）是一种口服药物，在英国可用于治疗“中度至重度阿尔茨海默病患者”。它与其他已获许可的治疗痴呆症的药物不同，是一种N-甲基-D-天冬氨酸（NMDA）受体拮抗剂。该公司宣称，通过美金刚治疗，“日常生活活动能力的改善有助于患者保持一定程度的独立性，更易于照料，有可能避免进入养老院护理”。我们评估了美金刚治疗痴呆症的疗效，并讨论了它在阿尔茨海默病患者管理中的地位。